MedTrace Logo

OA for Breast Cancer NAC Response

NCT05337280 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-12

No results posted yet for this study

Summary

This is an early research and development study. The objective of this study is to determine the feasibility of the Imagio OA/US Breast Imaging System to detect complete breast cancer pathologic response to neoadjuvant therapy as assessed by functional optoacoustic features, vascular features and relative degrees of oxygenation/deoxygenation

Conditions

Interventions

DEVICE

Imagio OA/US

Imagio optoacoustic/ultrasound

Sponsors & Collaborators

  • American College of Radiology

    collaborator OTHER

  • Seno Medical Instruments Inc.

    lead INDUSTRY

Principal Investigators

  • Basak Dogan, MD · UT Southwestern

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2023-01-04
Completion
2023-01-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05337280 on ClinicalTrials.gov